These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 11063789

  • 1. Relationship between serum cholesterol levels and meta-chlorophenylpiperazine-induced cortisol responses in healthy men and women.
    Terao T, Nakamura J, Yoshimura R, Ohmori O, Takahashi N, Kojima H, Soeda S, Shinkai T, Nakano H, Okuno T.
    Psychiatry Res; 2000 Oct 30; 96(2):167-73. PubMed ID: 11063789
    [Abstract] [Full Text] [Related]

  • 2. Effect of serum cholesterol levels on meta-chlorophenylpiperazine-evoked neuroendocrine responses in healthy subjects.
    Terao T, Yoshimura R, Ohmori O, Takano T, Takahashi N, Iwata N, Suzuki T, Abe K.
    Biol Psychiatry; 1997 May 01; 41(9):974-8. PubMed ID: 9110103
    [Abstract] [Full Text] [Related]

  • 3. Gender-dependent dissociation between oxytocin but not ACTH, cortisol or TSH responses to m-chlorophenylpiperazine in healthy subjects.
    Bagdy G, Arato M.
    Psychopharmacology (Berl); 1998 Apr 01; 136(4):342-8. PubMed ID: 9600579
    [Abstract] [Full Text] [Related]

  • 4. Headache and cortisol responses to m-chlorophenylpiperazine are highly correlated.
    Gordon ML, Lipton RB, Brown SL, Nakraseive C, Russell M, Pollack SZ, Korn ML, Merriam A, Solomon S, van Praag HM.
    Cephalalgia; 1993 Dec 01; 13(6):400-5. PubMed ID: 8313453
    [Abstract] [Full Text] [Related]

  • 5. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo.
    Pallanti S, Bernardi S, Quercioli L, DeCaria C, Hollander E.
    CNS Spectr; 2006 Dec 01; 11(12):956-64. PubMed ID: 17146409
    [Abstract] [Full Text] [Related]

  • 6. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects.
    Anand A, Charney DS, Delgado PL, McDougle CJ, Heninger GR, Price LH.
    Am J Psychiatry; 1994 Nov 01; 151(11):1626-30. PubMed ID: 7943451
    [Abstract] [Full Text] [Related]

  • 7. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.
    Mueller EA, Murphy DL, Sunderland T.
    J Clin Endocrinol Metab; 1985 Dec 01; 61(6):1179-84. PubMed ID: 4055985
    [Abstract] [Full Text] [Related]

  • 8. Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects.
    Broocks A, Meyer T, Gleiter CH, Hillmer-Vogel U, George A, Bartmann U, Bandelow B.
    Psychopharmacology (Berl); 2001 May 01; 155(3):234-41. PubMed ID: 11432685
    [Abstract] [Full Text] [Related]

  • 9. Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT(1A) receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects.
    Schwartz PJ, Turner EH, Garcia-Borreguero D, Sedway J, Vetticad RG, Wehr TA, Murphy DL, Rosenthal NE.
    Psychiatry Res; 1999 Apr 19; 86(1):9-28. PubMed ID: 10359479
    [Abstract] [Full Text] [Related]

  • 10. The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia.
    Scheepers FE, Gespen de Wied CC, Kahn RS.
    J Clin Psychopharmacol; 2001 Dec 19; 21(6):575-82. PubMed ID: 11763004
    [Abstract] [Full Text] [Related]

  • 11. Studies of serotonin function in anorexia nervosa.
    Brewerton TD, Jimerson DC.
    Psychiatry Res; 1996 Apr 16; 62(1):31-42. PubMed ID: 8739113
    [Abstract] [Full Text] [Related]

  • 12. Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia.
    Brewerton TD, Mueller EA, Lesem MD, Brandt HA, Quearry B, George DT, Murphy DL, Jimerson DC.
    Arch Gen Psychiatry; 1992 Nov 16; 49(11):852-61. PubMed ID: 1444722
    [Abstract] [Full Text] [Related]

  • 13. Allelic variants of the serotonin(2C) receptor and neuroendocrinological responses to the serotonin(2C) receptor agonist m-chlorophenylpiperazine in healthy male volunteers.
    Kühn KU, Quednow BB, Bagli M, Meyer K, Feuchtl A, Westheide J, Frahnert C, Maier W, Rao ML.
    Pharmacopsychiatry; 2002 Nov 16; 35(6):226-30. PubMed ID: 12518270
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
    Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW.
    Biol Psychiatry; 1991 Nov 15; 30(10):973-84. PubMed ID: 1756202
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics.
    Buydens-Branchey L, Branchey M, Fergeson P, Hudson J, McKernin C.
    Alcohol Clin Exp Res; 1997 Apr 15; 21(2):220-6. PubMed ID: 9113256
    [Abstract] [Full Text] [Related]

  • 19. Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects.
    Benjamin J, Greenberg BD, Murphy DL.
    Psychopharmacology (Berl); 1996 Sep 15; 127(2):140-9. PubMed ID: 8888380
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.